News- EIKRA

The Therapies Scientific Committee (TSC) is establishing a Task Force on Drug Repurposing Guidebook to help developers (of all kinds) navigating the rare disease landscape and identifying specific tools and practices of relevance for repurposing projects. The creation of the Development Guidebook will focus on repurposing approaches, following the same successful methodology used for the […]

IRDiRC is pleased to announce the election of Dr David Pearce, President of Innovation, Research & World Clinics, Sanford Health (USA), as the next Chair of the IRDiRC Consortium Assembly. Dr Pearce is replacing Dr Lucia Monaco, ex Lead of the Research Impact and Strategic Analysis team at Fondazione Telethon (Italy). Ms Samantha Parker, Chief Patient Access Officer at InnoSkel […]

We are proud to announce the publication of a commentary on 10 years of progress and challenges of IRDiRC in the prestigious journal Nature Reviews Drug Discovery. The article summarizes IRDiRC’s vision and goals and highlights its achievements and prospects after its first decade (2011–2021). The commentary has been authored by Lucia Monaco (Consortium Assembly […]

The Therapies Scientific Committee (TSC) is establishing a Task Force to characterize specific commonalities amongst a large group of “disregarded” rare diseases, with the potential secondary aims to identify removable roadblocks that may foster future research and development. The PLUTO project aims at using an integrated database search approach to: identify and classify the groups of rare […]

The International Rare Diseases Research Consortium (IRDiRC) has published the results of its COVID-19 survey in the Rare Disease and Orphan Drugs Journal.  The ambitious goals set by IRDiRC by 2027 to fulfill the vision of providing diagnosis and treatments to rare diseases (RDs) patients within one year of coming to medical attention have been challenged […]